Abstract : Polyaminocarboxylic acids have widely been used as antidotes in heavy metal intoxication, however their hydrophilic nature renders them to be mostly distributed extracellularly.
Handling of chronic cadmium poisoning requires decorporation of the metal from the intracellular binding sites by chelating agents followed by elimination of stable and diffusable metal-chelate complex from the body1,2). In order to develop a successful therapeutic protocol for cadmium intoxication, approaches have been made mainly towards development of newer chelating agents.
Diethylenetriamine-pentaacetic acid (DTPA), cyclohexane-diamine-tetraacetic acid (CDTA) and triethylene-tetramine-hexaacetic acid (TTHA) have successfully been used in decorporating cadmium from the body of exposed animals3). Since most of the potent chelating agents are hydrophilic in nature they are distributed extracellularly and thus are unable to remove the intracellularly bound metal2,4). Recent studies including those conducted by us have shown that the efficacy of the chelating agents viz DTPA, dimercaptopropanesulfonate (DMPS) and dimercaptosuccinic acid (DMSA) in the amelioration of cadmium toxicity could be enhanced by their encapsulation in liposomes5-7). It has been further observed that liposomal encapsulation of drugs results in its prolonged circulation in the blood6-8) and enhanced uptake by the tissue resulting in the reduced toxicity due to its sustained release in the biological system. Further, carrier potential of TTHA was most effective in mobilizing cadmium from liver, kindney and spleen of cadmium exposed animals followed by DRV-TTHA and free TTHA (cf. table-1). Enhancement in excretion of cadmium through urine and its elimination via feces was also observed by all the three treatments. Relatively highest cumulative excretion of cadmium by SUV-TTHA treatment is in correlation with the pattern of cadmium mobilization from the body organs (cf. Fig. 1 and 2 ). The higher efficacy of SUV-TTHA may be due to the fact that the higher curvature of smaller liposomes gives rise to a lower surface pressure than the larger liposomes making them more stable and available for circulation in blood for longer duration12). The delivery of TTHA via SUV to intracellular sites could thus be facilitated by its smaller size (80-100 nm) compared to large sized DRV (250-300 nm)12). The relative ineffectiveness of TTHA given via DRV could thus be due to their retention in body for shorter duration and release of the entrapped material extracellularly. The results of the present investigation demonstrate that encapsulaton of chelating agents in liposomes of smaller size considerably improves chelation therapy. Further studies involving modulation in composition of liposomes are in progress which may provide significant information. 
